The multiple kinase inhibitor nintedanib, one of the two drugs currently approved for treating IPF, has been reported to enhance SHP-1 activity, leading to the dephosphorylation of pro-apoptotic factors and eventually inducing apoptosis of chronic lymphocytic leukemia cells [54]. This evidence concerns the gene PTPN6 and idiopathic pulmonary fibrosis.